Key facts
- Mantle Therapeutics’s last known valuation is $15.3M (Nov 2024).
- It has raised $3.5M; the latest was Early Stage VC in Dec 2025.
- Notable investors include RTW Investments, AIN Ventures.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Mantle Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Mantle Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mantle Therapeutics
Operator of a biotechnology research company intended to develop treatments for rare fatal diseases that lack curative therapies. The company's platform spans multiple diseases and therapeutic technologies, enabling healthcare providers to cure the disease of their patients.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 4
- Website
- mantletherapeutics.com/
- Ownership
- Privately Held (backing)
Mantle Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mantle Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mantle Therapeutics in its N-PORT filings yet. We sweep new filings monthly.